Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1511P - A real world study of pyrotinib in patients with HER-2 positive/mutations tumors excluding breast cancer


17 Sep 2020


E-Poster Display


Jun Qian


Annals of Oncology (2020) 31 (suppl_4): S874-S880. 10.1016/annonc/annonc264


J. Qian1, H. Yang1, C. Zhu2, J. Tan1, Z. Liu3, M. Chen4, R. Zhou5

Author affiliations

  • 1 Oncology Department, Suzhou Municipal Hospital (No. 2 People's Hospital), 215000 - Suzhou/CN
  • 2 Oncology department , The first affiliated hospital of suzhou university, Suzhou/CN
  • 3 Oncology Department, The first people's hospital of zhangjiagang city, 215000 - Zhangjiagang/CN
  • 4 Oncology department , The first people's hospital of kunshan, Kunshan/CN
  • 5 Oncology Department, The 904 hospital of the PLA joint logistic support force, Wuxi/CN


Abstract 1511P


Pyrotinib have improved clinical outcomes in HER-2 positive breast cancer and are explored as potential treatments for HER-2 positive/mutations tumors other than breast cancer. We aimed to evaluate the efficacy and safety of pyrotinib for the treatment of the patients with HER-2 positive/mutations tumors other than breast cancer in clinical practice.


This is a multicentre, retrospective study. The clinical data of patients with HER-2 positive/mutations tumors excluding breast cancer were collected in 14 hospitals in Suzhou and Wuxi City from September 2018 to May 2019. Patients historically confirmed overexpression of HER-2 protein by ICH3+/ISH+ or HER-2 mutations on targeted NGS was included. All patients received any regimens based on pyrotinib.


Total 25 pts with HER-2 positive/mutations were enrolled. The median age was 64 years (range 37-73 years). There were 10 lung cancer, 9 gastric cancer, 2 colorectal cancer, 2 thymic cancer, 1 ovarian cancer and 1 gallbladder cancer. Patients received pyrotinib as <3rd-line therapy, 3rd-line therapy, >3rd-line therapy accounted for 20% (5), 56% (14), and 24% (6), respectively. Seven pts received pyrotinib monotherapy, 18 pts received combination therapy, including 11 combined with capecitabine, 2 with albumin-bound paclitaxel, 1 with trastuzumab, 1 with osimertinib, 1 with bevacizumab,1 with pemetrexed, and 1 with irinotecan. 21 (84.0%) pts received 400 mg pyrotinib once daily as initial dose, 2 (8%) pts received 320 mg, 2 (8%) pts received 160 mg. Total 23 pts were eligible for efficacy evaluation, 12 pts achieved PR (4 pts with lung cancer, 4 pts with gastric cancer, 2 pts with colorectal cancer, 2 pts with thymic cancer), 9 pts were SD and 2 pts were PD. The ORR was 52.2% and the DCR was 91.3%. The mPFS was 3.5 months (95%CI: 2.2-5.0 months), mOS was 9.6 months (95%CI: 4.4 months-NR). The main AE was diarrhea in 23 (92%) cases, Grade 1-2 diarrhea were recored in 18 (72.0%) cases, and 5 (20%) cases reported grade 3 diarrhea.


The retrospective study showed that pyrotinib showed good efficacy and safety in patients with HER-2 positive/mutation solid tumors, not only in HER-2 positive breast cancer. Prospective studies are warranted to further confirm its efficacy and safety.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study



Suzhou municipal health and family planning commission (GSWS2019019).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings